Glenmark Pharmaceuticals Secures USFDA Approval for Progesterone Vaginal Inserts
Glenmark Pharma gets USFDA nod for Progesterone Vaginal Inserts
Business Standard
Image: Business Standard
Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (USFDA) for its Progesterone Vaginal Inserts, 100 mg, which are bioequivalent to Ferring Pharmaceuticals' Endometrin. This approval supports Glenmark's commitment to enhancing women's healthcare in the U.S.
- 01Glenmark Pharmaceuticals received USFDA approval for Progesterone Vaginal Inserts, 100 mg.
- 02The product is bioequivalent to Endometrin Vaginal Inserts by Ferring Pharmaceuticals.
- 03This approval is part of Glenmark's strategy to expand women's healthcare offerings.
- 04Glenmark reported a 15.9% increase in net profit to ₹403.21 crore in Q3 FY26.
- 05Despite the approval, Glenmark's shares fell by 1.39% on the BSE.
Advertisement
In-Article Ad
Glenmark Pharmaceuticals has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Progesterone Vaginal Inserts, 100 mg. This product is considered bioequivalent and therapeutically equivalent to Endometrin Vaginal Inserts, 100 mg, manufactured by Ferring Pharmaceuticals. The distribution of the product in the U.S. will be handled by Glenmark Pharmaceuticals Inc., USA. Marc Kikuchi, President & Business Head for North America, emphasized the company's commitment to providing quality and affordable medicines, particularly in women's healthcare. This approval is seen as a significant addition to Glenmark's portfolio. In its financial performance, Glenmark reported a 15.9% increase in consolidated net profit, reaching ₹403.21 crore (approximately $49 million USD), alongside a 17.8% rise in revenue from operations to ₹3,888 crore (roughly $466 million USD) for the third quarter of fiscal year 2026 compared to the same period last year. However, the company's shares experienced a decline of 1.39%, closing at ₹2,144.05 (approximately $26 USD) on the Bombay Stock Exchange (BSE).
Advertisement
In-Article Ad
The approval of Progesterone Vaginal Inserts may improve access to essential medications for women in the U.S., potentially affecting healthcare costs and availability.
Advertisement
In-Article Ad
Reader Poll
Do you think the approval of new medications like Progesterone Vaginal Inserts is important for women's healthcare?
Connecting to poll...
More about Glenmark Pharmaceuticals
Read the original article
Visit the source for the complete story.